Buyback yield (TTM)
1.82%
Shareholder yield (TTM)
2.86%
5Y share count change
1.2%
Buyback spend (TTM)
$600.04M
Cumulative buybacks
$2.07B
Key takeaways
- ResMed (RMD) repurchased about $600.04M of stock over the trailing twelve months.
- Diluted share count is up 1.2% over the last ~5 fiscal years — equity issuance and stock-based compensation are outpacing repurchases.
- TTM buyback ÷ stock-based-comp ratio of 5.90× — repurchases more than cover SBC dilution.
- TTM repurchases used about 43% of free cash flow remaining after dividends.
Dividend & buyback yield over time for ResMed (RMD)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for ResMed (RMD)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for ResMed (RMD)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for ResMed (RMD)
Latest: $300.02M
Overview
2025's annual buyback spend for ResMed (RMD) came in at $300.02M – surged 100.0% year-over-year.
Across 2015–2025 (10 years), ResMed buyback spend produced a CAGR of +6.5% – sustaining 2 straight years of year-over-year growth.
ResMed buyback spend declined from $392.74M in 2012 to $300.02M in 2025, a 23.6% drawdown.
The highest annual buyback spend of $392.74M was reported in 2012. The lowest in the available history was $0.00 in 1993.
ResMed Buyback Spend 2025: $300.02M
2025's buyback spend for ResMed came in at $300.02M, surged 100.0% from 2024.
ResMed Buyback Spend 2024: $150.01M
ResMed buyback spend in 2024 was $150.01M.
ResMed Buyback Spend 2023: $0.00
ResMed buyback spend in 2023 was $0.00.
ResMed Buyback Spend 2022: $0.00
ResMed buyback spend in 2022 was $0.00.
ResMed Buyback Spend 2021: $0.00
ResMed buyback spend in 2021 was $0.00.
See more financial history for ResMed (RMD).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $300.02M | $91.66M | $208.36M | 0.79% | 0.15B | -0.1% | |
| 2024 | $150.01M | $80.18M | $69.83M | 0.55% | 0.15B | +0.1% | |
| 2023 | $0.00 | $71.14M | −$71.14M | — | 0.15B | +0.3% | |
| 2022 | $0.00 | $65.26M | −$65.26M | — | 0.15B | +0.4% | |
| 2021 | $0.00 | $63.93M | −$63.93M | — | 0.15B | +0.5% | |
| 2020 | $0.00 | $57.56M | −$57.56M | — | 0.15B | +0.8% | |
| 2019 | $22.84M | $52.07M | −$29.23M | 0.13% | 0.14B | +0.3% | |
| 2018 | $53.80M | $48.41M | $5.39M | 0.36% | 0.14B | +1.1% | |
| 2017 | $0.00 | $45.92M | −$45.92M | — | 0.14B | +0.6% | |
| 2016 | $102.06M | $46.41M | $55.65M | 1.15% | 0.14B | -0.7% | |
| 2015 | $160.30M | $47.85M | $112.44M | 2.02% | 0.14B | -1.2% | |
| 2014 | $202.17M | $43.46M | $158.71M | 2.84% | 0.14B | -1.4% | |
| 2013 | $186.26M | $38.16M | $148.10M | 2.92% | 0.15B | -1.9% | |
| 2012 | $392.74M | $30.59M | $362.16M | 8.82% | 0.15B | -5.0% | |
| 2011 | $163.34M | $30.81M | $132.53M | 3.46% | 0.16B | +1.4% | |
| 2010 | $131.08M | $29.73M | $101.35M | 2.85% | 0.16B | +0.6% | |
| 2009 | $68.59M | $25.52M | $43.08M | 2.24% | 0.15B | -2.0% | |
| 2008 | $96.56M | $0.00 | $96.56M | 3.57% | 0.16B | +0.6% | |
| 2007 | $2.09M | $0.00 | $2.09M | 0.07% | 0.16B | +1.4% | |
| 2006 | $0.00 | $0.00 | $0.00 | — | 0.15B | +3.0% | |
| 2005 | $10.97M | $0.00 | $10.97M | 0.48% | 0.15B | +6.7% | |
| 2004 | $19.03M | $0.00 | $19.03M | 1.10% | 0.14B | +2.0% | |
| 2003 | $3.54M | $0.00 | $3.54M | 0.27% | 0.14B | +1.1% | |
| 2002 | $7.87M | $0.00 | $7.87M | 0.86% | 0.14B | +1.8% | |
| 2001 | $0.00 | $0.00 | $0.00 | — | 0.13B | +3.7% | |
| 2000 | $0.00 | $0.00 | $0.00 | — | 0.13B | +4.0% | |
| 1999 | $0.00 | $0.00 | $0.00 | — | 0.12B | +3.3% | |
| 1998 | $0.00 | $0.00 | $0.00 | — | 0.12B | +2.7% | |
| 1997 | $0.00 | $0.00 | $0.00 | — | 0.12B | +4.1% | |
| 1996 | $0.00 | $0.00 | $0.00 | — | 0.11B | — | |
| 1995 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1994 | $300.00K | $0.00 | $300.00K | — | — | — | |
| 1993 | $0.00 | $0.00 | $0.00 | — | — | — |
- 2025$300.02M
- 2024$150.01M
- 2023$0.00
- 2022$0.00
- 2021$0.00
- 2020$0.00
- 2019$22.84M
- 2018$53.80M
- 2017$0.00
- 2016$102.06M
- 2015$160.30M
- 2014$202.17M
- 2013$186.26M
- 2012$392.74M
- 2011$163.34M
- 2010$131.08M
- 2009$68.59M
- 2008$96.56M
- 2007$2.09M
- 2006$0.00
- 2005$10.97M
- 2004$19.03M
- 2003$3.54M
- 2002$7.87M
- 2001$0.00
- 2000$0.00
- 1999$0.00
- 1998$0.00
- 1997$0.00
- 1996$0.00
- 1995$0.00
- 1994$300.00K
- 1993$0.00
Buybacks vs stock-based compensation for ResMed (RMD)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 5.90×.
Buybacks vs dividends (share of cash returned) for ResMed (RMD)
How ResMed splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as ResMed, ranked by their latest buyback spend.
| $5.95B | |
| $5.54B | |
| $5.08B | |
| $4.11B | |
| $980.00M | |
| $216.35M | |
| $0.00 | |
| $0.00 |
- $5.95B
- $5.54B
- $5.08B
- $4.11B
- $980.00M
- $216.35M
- $0.00
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $1.41B (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation